Genetically engineered probiotics like ZB183 have shown potential benefits; in a MASH murine model, Zbiotics downregulated the cGAS-STING pathway, reducing liver inflammation and steatosis and improving colonic health, indicating its potential as a novel therapeutic candidate [101]. The gene discussed is CGAS; the disease is Hepatitis.